top of page
Recruiting

NCT04975399: Phase 1: Study to Evaluate the Safety and Tolerability of CC-92328 in Participants RRMM

Updated: May 25, 2022

NCT04975399: Phase 1: Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma


TriNKET

Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma


This Phase 1, first-in-human (FIH), clinical study of CC-92328 will explore the safety, tolerability and preliminary biological and clinical activity of CC-92328 as a single-agent in the setting of relapsed and/or refractory multiple myeloma (R/R MM). The study will be conducted in two parts: monotherapy dose escalation (Part A) and monotherapy dose expansion (Part B).


Sponsor

Celgene


Multiple Locations

International Study

 

ClinicalTrials.gov Identifier: NCT04975399


Official Title: A Phase 1, Multi-center, Open-label, Dose Finding Study of CC-92328 in Subjects With Relapsed and/or Refractory Multiple Myeloma


First Posted : July 23, 2021


Click here to see details on ClinicalTrials.gov

 

Drug: CC-92328

 

CC-92328

(DF 3001)

NK cell engager


TriNKET

tri-specific natural killer cell engager therapy

 

The Phase 1 clinical trial for the CC-92328 TriNKET is a first-in-human study which will explore the safety, tolerability and preliminary biological and clinical activity of CC-92328 as a single-agent in the setting of relapsed and/or refractory multiple myeloma (R/R MM). Additional information about the trial, including eligibility criteria, can be found at: https://clinicaltrials.gov (ClinicalTrials.gov Identifier: NCT04975399).


Natural killer cell engagers in cancer immunotherapy

 

Locations

United States, Alabama

United States, Arizona

United States, Florida

United States, Maryland

United States, New York

United States, Wisconsin

Canada, Alberta

Canada, Nova Scotia

Canada, Ontario

Canada, Quebec

Europe

Spain

Sweden











Posts Archive
bottom of page